While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...

“The field of gene therapy research has made tremendous strides in recent years, and we are pleased to be able to further enhance our leadership position in this area through this transaction with ...

Canadian freestyle skier Mikael Kingsbury's streak of World Cup mogul victories ended at five on Friday. France's Benjamin Cavet, whose last victory was in Idre Fjäll, Sweden, in December 2020 ...

When will health care costs become truly unsustainable? Is there an alternative to these group health plans that can help combat soaring costs? After a brief respite during the pandemic, employer ...

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a biotechnology firm specializing in pharmaceutical preparations, announced the appointment of Dr. Mikael Dolsten to its Board of Directors, effective last ...

Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer was announced earlier this year. In his new ...

He will succeed Dr. Mikael Dolsten, whose departure was announced earlier this year. This new appointment will be effective from Jan. 1, 2025. Dr. Boshoff currently serves as the chief oncology ...

Leerink notes Pfizer (PFE) announced that Chris Boshoff will become the new Chief Scientific Officer, succeeding Mikael Dolsten. The firm views Boshoff as a strong choice for CSO given his ...

(Reuters) - Pfizer has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing for more than a year, as its R&D chief, WSJ reported on Wednesday.

Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer was announced earlier this year.

Dr. Boshoff, who most recently served as Chief Oncology Officer and Executive Vice President, will succeed Dr. Mikael Dolsten whose departure from Pfizer was announced earlier this year. In his new ...

Rocket Pharmaceuticals has further announced the appointment of Dr. Mikael Dolsten to its Board of Directors. Additionally, the company has initiated a rolling Biologics License Application with the U ...